DSMFF:OTC-DSM-Firmenich AG (USD)

COMMON STOCK | Specialty Chemicals |

Last Closing

USD 122.89

Change

0.00 (0.00)%

Market Cap

USD 33.23B

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

DSM-Firmenich AG provides solutions for nutrition, health, and beauty businesses in the Switzerland, Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. It operates through Perfumery & Beauty; Taste, Texture & Health; Health, Nutrition & Care; and Animal Nutrition & Health segments. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, including flavors, natural extracts, and sugar reduction; and food enzymes, cultures, hydrocolloids, proteins, natural colorants, nutritional ingredients, premixes and yeast extracts solutions. The Animal Nutrition & Health segment offers animal proteins, as well as vitamins, performance solutions, and data-driven precision services for the animal production industry. The Health, Nutrition & Care segment provides solutions for the early life nutrition, dietary supplement, pharmaceutical, biomedical materials, and nutrition improvement markets. This segment offers vitamins, nutritional lipids, minerals, carotenoids, botanical nutraceuticals, digestive enzymes, probiotics and prebiotics, active pharmaceutical ingredients, as well as a range of biomedical solutions; premix, market-ready solutions, and personalized nutrition solutions; and regulatory affairs and formulation expertise services, and customized solutions. The company was founded in 1902 and is based in Kaiseraugst, Switzerland.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Specialty Chemicals

Symbol Name Price(Change) Market Cap
AIQUF L'Air Liquide S.A

-2.66 (-1.46%)

USD 106.63B
AIQUY Air Liquide SA ADR

-0.42 (-1.15%)

USD 106.62B
GVDBF Givaudan SA

N/A

USD 48.08B
SKFOF Sika AG

-5.63 (-2.02%)

USD 46.78B
SXYAY Sika AG ADR

-0.50 (-1.76%)

USD 45.85B
GVDNY Givaudan SA ADR

-0.61 (-0.63%)

USD 44.98B
NVZMF Novozymes A/S B

+0.44 (+0.71%)

USD 30.14B
EMSHF EMS-CHEMIE HOLDING AG

N/A

USD 18.45B
SYIEF Symrise AG

N/A

USD 18.31B
NPPHY Nippon Paint Holdings Co. Ltd.

+0.05 (+1.20%)

USD 16.30B

ETFs Containing DSMFF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Specialty Chemicals) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 33.23B 93% A 97% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.